glp-1 receptor agonist type 1 diabetes randomized trial New Developments in Pharmacological Treatment of Obesity and 2 Diabetes—Beyond and within Agonists GLP-1 receptor agonists and cardiovascular
Description
Type 2 diabetes treatments in 2025 go beyond insulin therapy, with emphasis on oral GLP-1s, SGLT2 inhibitors, and once-weekly insulin formulations
The primary outcome being assessed is the time until the occurrence of the first cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina pectoris
(1998) 275:E80613
Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study [abstract 75]
Discuss with your provider whether lipid improvements alone are a treatment goal or whether weight loss and glycemic control take priority
Tirzepatide, in StatPearls [Internet]
